Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476890 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL24624826 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL31650964 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL13825188 | 0.71 | RAB9A (0.47) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL28452557 | 0.70 | ALDH1A1 (0.54) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL983728 | 0.70 | ALDH1A1 (0.54) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL5707057 | 0.70 | ALDH1A1 (0.56) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL13824907 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KDM4EPOLBMAPTCA2 | |
| SCHEMBL3308855 | 0.67 | ALDH1A1 (0.64) | ALDH1A1KDM4ECA2KMT2ASMN1; SMN2 | |
| SCHEMBL11894735 | 0.67 | ALDH1A1 (0.46) | ALDH1A1KDM4EPOLBMAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912414-A | Method for efficiently synthesizing Maculalactone A framework based on Suzuki-Miyaura cross coupling reaction | 山东大学 | 2025-05-02 | — | — | CN | disclosed |
| US-11339146-B2 | Compositions and methods for viral sensitization | Ottawa Hospital Research Institute and University of Ottawa (CA) | 2022-05-24 | — | — | US | disclosed |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200354351-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180112190-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2018-04-26 | — | — | US | disclosed |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2370413-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2015-07-09 | — | — | US | disclosed |
| US-8940891-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2370413-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010077275-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | PTGIR, PTGIS, TBXA2R | ALDH1A1 652/4885KDM4E 4766/4885POLB 702/4885 |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | ALDH1A1 683/4885KDM4E 4664/4885POLB 609/4885 |
| US-11339146-B2 | Compositions and methods for viral sensitization | CD4, CD74, HLA-DRB1 | ALDH1A1 3190/4885KDM4E 4560/4885POLB 1654/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 704/4885KDM4E 4845/4885POLB 655/4885 |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | ALDH1A1 683/4885KDM4E 4664/4885POLB 609/4885 |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 705/4885KDM4E 4845/4885POLB 654/4885 |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 704/4885KDM4E 4845/4885POLB 655/4885 |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | PTGIR, PTGIS, TBXA2R | ALDH1A1 652/4885KDM4E 4766/4885POLB 702/4885 |
| US-20200354351-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | ALDH1A1 4002/4885KDM4E 4385/4885POLB 1436/4885 |
| US-20180112190-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | ALDH1A1 4002/4885KDM4E 4385/4885POLB 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.